For example, in non-small cell lung cancer (NSCLC), targeted therapies are currently approved and preferred over cytotoxic chemotherapy for patients with sensitizing EGFR mutations1–4, ALK and ROS1 gene rearrangements5–8, and BRAF variants9. Here, ROS1 is linked to non-small cell lung carcinoma.